INNOVENT BIO: Masitinib approved for blood sugar control in adults with type 2 diabetes
Innovent Biologics announced that the new drug application for the second indication of Masitinib Injection has been approved for marketing by the National Medical Products Administration of China, for blood glucose control in adult patients with type 2 diabetes
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments